Phase II Study of GM-CSF to Overcome Herceptin-Resistant HER-2/Neu-Overexpressing Metastatic Breast Cancer
GM-CSF stimulates the immune system and may increase the effectiveness of Herceptin.
Before you can start treatment on this study, you will have what are called "screening
tests." These tests will help the doctor decide if you are eligible to take part in this
study. You will have a complete medical history and physical exam. This includes blood
tests (about 2 tea spoons), and x-rays. Women who are able to have children must have a
negative blood or urine pregnancy test.
If you are found to be eligible to take part in this study, you will receive trastuzumab
through a vein (IV) every week until the disease gets worse. GM-CSF will be injected under
the skin at least once a day until the white blood cell count is stable. GM-CSF will also
continue during the course of study until the disease progresses.
You will have further evaluation of your disease by computed tomography-CT scan, bone scan,
chest X-ray, etc. at 2, 4, 6, 9, 12, 18, and 24 months after the start of treatment. You
will have blood tests (about 2 tea spoons) at least twice a week until the appropriate dose
of GM-CSF is found. The dose may increase or decrease depending on the blood test.
You will have blood (about 2 tablespoons) drawn before treatment at the 2nd and 4th month,
and if the disease gets worse.
You will be removed from the study if the disease is progressing or severe side effects
This is an investigational study. The FDA has approved trastuzumab and GM-CSF, but their
use in this study is experimental. A total of 36 patients will take part in this study. All
will be enrolled at UT MD Anderson Cancer Center.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With Tumor Response (Stable Disease)
Number of participants with response defined as stable disease or better using Response Evaluation Criteria In Solid Tumors (RECIST) at the month 2 evaluation.
Naoto Ueno, MD, PhD
M.D. Anderson Cancer Center
United States: Institutional Review Board
|U.T.M.D. Anderson Cancer Center||Houston, Texas 77030|